A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR ("WET") AGE-RELATED MACULAR DEGENERATION (NV-AMD)
- Registry ID
- EUCTR2006-006358-86
- Source registry
- EUCTR
- Status
- Prematurely Ended
- Phase
- PHASE2
- Sponsor
- CoMentis, Inc., USA
- Start date
- 2007-04-27
- Completion date
- 2009-06-02
- Last update
- 2026-08-16
Conditions
- Neovascular ("wet") Age-related Macular Degeneration (NV- AMD)
Summary
The objectives of this study are to establish the safety of ATG003 and to determine preliminary efficacy of two doses of ATG003 compared to placebo. The primary objective is to compare the change in visual acuity from baseline to week 48 between the patients treated with ATG003 to those treated with placebo - the proportion of patients losing fewer than 15 ETDRS letters (3 lines) of visual acuity in the study eye, using a standardized refraction and testing protocol at a starting test distance of 4 meters.
Locations
View on source registry